Literature DB >> 29688878

Dispensary cannabidiol marijuana and first-episode mania.

Zahinoor Ismail1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29688878      PMCID： PMC5915243          DOI： 10.1503/jpn.180034

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  8 in total

Review 1.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

2.  Cannabinoid concentrations in Canada's regulated medical cannabis industry.

Authors:  George Mammen; Lauren de Freitas; Jürgen Rehm; Sergio Rueda
Journal:  Addiction       Date:  2017-01-25       Impact factor: 6.526

3.  Cannabidiol: Swinging the Marijuana Pendulum From 'Weed' to Medication to Treat the Opioid Epidemic.

Authors:  Yasmin L Hurd
Journal:  Trends Neurosci       Date:  2017-02-02       Impact factor: 13.837

4.  Cannabis with high cannabidiol content is associated with fewer psychotic experiences.

Authors:  Christian D Schubart; Iris E C Sommer; Willemijn A van Gastel; Rogier L Goetgebuer; René S Kahn; Marco P M Boks
Journal:  Schizophr Res       Date:  2011-05-17       Impact factor: 4.939

Review 5.  Cannabidiol as a Potential Treatment for Anxiety Disorders.

Authors:  Esther M Blessing; Maria M Steenkamp; Jorge Manzanares; Charles R Marmar
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Authors:  Robin M Murray; Harriet Quigley; Diego Quattrone; Amir Englund; Marta Di Forti
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

7.  Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Authors:  Eva M Marco; María S García-Gutiérrez; Francisco-Javier Bermúdez-Silva; Fabricio A Moreira; Francisco Guimarães; Jorge Manzanares; María-Paz Viveros
Journal:  Front Behav Neurosci       Date:  2011-10-05       Impact factor: 3.558

8.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.